Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 4/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | USP5 | P45974 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13634059 | 0.94 | ALK (0.36) | ALKJAK2L3MBTL1MAPTCHRM5 | |
| SCHEMBL13634050 | 0.94 | ALK (0.41) | ALKJAK2MAPTTHRBPKM | |
| SCHEMBL13622663 | 0.94 | ALK (0.48) | ALKL3MBTL1MAPTCHRM5THRB | |
| Trifluoroacetic Acid SCHEMBL4361782 | 0.90 | ALK (0.45) | ALKL3MBTL1CHRM5SMN1; SMN2RORC | |
| SCHEMBL4363845 | 0.89 | ALK (0.42) | ALKJAK2MAPTCHRM5THRB | |
| SCHEMBL13633105 | 0.88 | ALK (0.43) | ALKJAK2L3MBTL1SMN1; SMN2RORC | |
| SCHEMBL13622667 | 0.88 | ALK (0.49) | ALKPKMSMN1; SMN2RORCALDH1A1 | |
| SCHEMBL13633020 | 0.87 | ALK (0.41) | ALKJAK2L3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL13633106 | 0.87 | ALK (0.41) | ALKJAK2L3MBTL1SMN1; SMN2RORC | |
| SCHEMBL13633993 | 0.85 | ALK (0.41) | ALKJAK2L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | ALK 3/4885JAK2 1/4885L3MBTL1 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.